Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran∗). part II. dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers  Janine J.L Oberyé, Bernadette M.J.L Mannaerts, Jan A.M Huisman, Cees J Timmer  Fertility and Sterility  Volume 72, Issue 6, Pages 1006-1012 (December 1999) DOI: 10.1016/S0015-0282(99)00414-8

Figure 1 Log-linear plot of mean (±SD) serum ganirelix concentrations at steady state after multiple-dose SC administration of 0.125 mg, 0.25 mg, and 0.50 mg of ganirelix (15 subjects per dose group). Oberyé. Ganirelix (Antagon/Orgalutran). Fertil Steril 1999. Fertility and Sterility 1999 72, 1006-1012DOI: (10.1016/S0015-0282(99)00414-8)

Figure 2 Median predose serum hormone concentrations during multiple-dose SC administration of 0.125 mg (▵), 0.25 mg (•), and 0.50 mg (□) of ganirelix (15 subjects per dose group). (A), LH concentrations. (B), FSH concentrations. (C), E2 concentrations. Oberyé. Ganirelix (Antagon/Orgalutran). Fertil Steril 1999. Fertility and Sterility 1999 72, 1006-1012DOI: (10.1016/S0015-0282(99)00414-8)

Figure 3 Median serum hormone concentrations during one dosing interval and recovery after multiple-dose SC administration of 0.125 mg (▵), 0.25 mg (•), and 0.50 mg (□) of ganirelix (15 subjects per dose group). (A), LH concentrations. (B), FSH concentrations. (C), E2 concentrations. Oberyé. Ganirelix (Antagon/Orgalutran). Fertil Steril 1999. Fertility and Sterility 1999 72, 1006-1012DOI: (10.1016/S0015-0282(99)00414-8)